Shares of the highly popular biotech stock ChemoCentryx (NASDAQ: CCXI) ticked up a few notches after a Wall Street analyst upgraded the stock to buy. Stifel analyst Dae Gon Ha thinks a recent development regarding the clinical-stage biotech's lead candidate is a pretty big deal that the rest of the stock market has mostly overlooked.
Does recent receptivity from the Food and Drug Administration make ChemoCentryx a good stock to buy now, or is there another heartbreak on the horizon? Let's compare the good news to the bad to find out.
Image source: Getty Images.
For further details see:
Is Now the Time to Buy ChemoCentryx Stock?